22 Nov 2021 Dr. Jamie Falk: A Deep Dive into SGLT2 Inhibitors: What comes up to the surface for individual patients with diabetes?
In this engaging discussion lead by Dr. Jamie Falk, delivered at the Therapeutics Initiative at our Oct 16th conference, “Bringing Best Evidence to Clinicians“, Jamie dove deep into a pool of relatively studies of the effects of newer drugs for diabetes.
Dr. Falk is an associate professor at the College of Pharmacy, at the University of Manitoba and practices as an Extended Practice Pharmacist in Winnipeg.
In this talk he discusses two important questions: Does A1c matter and how well do these newer drugs work against cardiovascular (CV) risk or Chronic Kidney Disease (CKD)? He also dives into the most important question: how much risk reduction is important to you or your patients?
Claudia O'Donnell
Posted at 13:23h, 03 DecemberGreat talk. I always like to see/hear your perspective in the eyes of the patient. What is important to our patient. We get caught up treating numbers all the time and not look at patient’s quality of life